ES2113878T3 - Proteina c hibrida. - Google Patents
Proteina c hibrida.Info
- Publication number
- ES2113878T3 ES2113878T3 ES91901991T ES91901991T ES2113878T3 ES 2113878 T3 ES2113878 T3 ES 2113878T3 ES 91901991 T ES91901991 T ES 91901991T ES 91901991 T ES91901991 T ES 91901991T ES 2113878 T3 ES2113878 T3 ES 2113878T3
- Authority
- ES
- Spain
- Prior art keywords
- human
- protein
- modified
- molecules
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
- C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
PROTEINA C HIBRIDA LAS MOLECULAS DE LA PROTEINA C HUMANA SE MODIFICAN PARA PROPORCIONAR UNA MAYOR RESISTENCIA A LA INACTIVACION MEDIANTE FACTORES DE PLASMA HUMANOS AL TIEMPO QUE SE MANTIENE SUSTANCIALMENTE LA ACTIVIDAD BIOLOGICA DE LA PROTEINA C HUMANA. LAS MODIFICACIONES SE HACEN NORMALMENTE EN LA CADENA PESADA DE LA PROTEINA C, CUYA CADENA PUEDE SER SUSTITUIDA POR UNA CADENA PESADA DE PROTEINA C DE ORIGEN NO HUMANO, COMO POR EJEMPLO BOVINO, LO QUE DA LUGAR A UNA MOLECULA DE LA PROTEINA C QUIMERICA. LA CADENA PESADA DE LA PROTEINA C HUMANA SE PUEDE MODIFICAR TAMBIEN PARA QUE SEA TIPO HUMANA PUESTO QUE AL MENOS UN AMINOACIDO DE UNA SECUENCIA NO HUMANA SE PUEDE SUSTITUIR POR EL RESIDUO O RESIDUOS CORRESPONDIENTES DE LA SECUENCIA HUMANA, PERMITIENDO ASI QUE LA MOLECULA SIGA TENIENDO CARACTERISTICAS HUMANAS AL TIEMPO QUE SIGUE PRESENTANDO UNA MAYOR RESISTENCIA A LA INACTIVACION. TAMBIEN SE INCLUYEN LOS METODOS PARA PRODUCIR LAS MOLECULAS DE PROTEINA C MODIFICADAS Y LAS COMPOSICIONES FARMACEUTICAS DE LAS MISMAS. LAS MOLECULAS MODIFICADAS, QUE TIENEN UNA VIDA MEDIA MAYOR EN EL PLASMA HUMANO, SON PARTICULARMENTE UTILES PARA EL TRATAMIENTO DE DESORDENES RELACIONADOS CON LA COAGULACION, TALES COMO UNA DEFICIENCIA DE PROTEINA C O TROMBOSIS O PARA FOMENTAR LA FIBRILINOSIS DE UN PACIENTE.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45885689A | 1989-12-29 | 1989-12-29 | |
US51537890A | 1990-04-27 | 1990-04-27 | |
PCT/US1990/007693 WO1991009960A1 (en) | 1989-12-29 | 1990-12-28 | Hybrid protein c |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2113878T3 true ES2113878T3 (es) | 1998-05-16 |
Family
ID=27039137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91901991T Expired - Lifetime ES2113878T3 (es) | 1989-12-29 | 1990-12-28 | Proteina c hibrida. |
Country Status (11)
Country | Link |
---|---|
US (1) | US5766921A (es) |
EP (1) | EP0506821B1 (es) |
JP (1) | JP3270462B2 (es) |
AT (1) | ATE163048T1 (es) |
AU (1) | AU7168591A (es) |
CA (1) | CA2071630C (es) |
DE (1) | DE69032029T2 (es) |
DK (1) | DK0506821T3 (es) |
ES (1) | ES2113878T3 (es) |
GR (1) | GR3026414T3 (es) |
WO (1) | WO1991009960A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT397615B (de) * | 1991-05-14 | 1994-05-25 | Immuno Ag | Arzneimittel enthaltend protein c |
SV1999000067A (es) * | 1998-06-01 | 2000-07-06 | Lilly Co Eli | Proteina humana c polipeptida ref. x-12279 |
US6998122B1 (en) | 1999-04-30 | 2006-02-14 | Eli Lilly And Company | Protein C derivatives |
AU4188500A (en) * | 1999-04-30 | 2000-11-17 | Eli Lilly And Company | Protein c derivatives |
JP2003514545A (ja) * | 1999-11-19 | 2003-04-22 | イーライ・リリー・アンド・カンパニー | プロテインc誘導体 |
ES2234807T3 (es) | 2000-02-02 | 2005-07-01 | Eli Lilly And Company | Derivados de proteina c. |
EP1263943A1 (en) | 2000-02-11 | 2002-12-11 | Eli Lilly & Company | Protein c derivatives |
US6933367B2 (en) * | 2000-10-18 | 2005-08-23 | Maxygen Aps | Protein C or activated protein C-like molecules |
JP4071105B2 (ja) * | 2000-10-18 | 2008-04-02 | マキシゲン・エイピーエス | プロテインcまたは活性化プロテインc様分子 |
JP2004535461A (ja) * | 2001-07-19 | 2004-11-25 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | プロテインcの不活性化を抑制するための銅キレート剤の使用 |
US20070142272A1 (en) * | 2003-01-24 | 2007-06-21 | Zlokovic Berislav V | Neuroprotective activity of activated protein c independent of its anticoagulant activity |
WO2006014839A2 (en) * | 2004-07-23 | 2006-02-09 | The University Of Rochester | Activated protein c inhibits undesirable effects of plasminogen activator in the brain |
BRPI0514396A2 (pt) * | 2004-08-17 | 2009-05-12 | Csl Behring Gmbh | polipeptìdeos dependentes de vitamina k modificada |
EP2242875A4 (en) * | 2008-01-15 | 2012-04-04 | Univ British Columbia | PROTEIN C RS2069915 AS A SURVIVOR RESPONSE PREDICTOR AND ADMINISTRATION OF PROTEIN C OR AN ACTIVE PROTEIN C COMPOUND |
WO2012068519A2 (en) | 2010-11-19 | 2012-05-24 | Sirius Genomics Inc. | Markers associated with response to activated protein c administration, and uses thereof |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4711848A (en) * | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
US4902614A (en) * | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
DE3688900T3 (de) * | 1985-06-27 | 1998-06-10 | Univ Washington | Expression von Protein C. |
US4959318A (en) * | 1985-06-27 | 1990-09-25 | Zymogenetics, Inc. | Expression of protein C |
EP0245949B1 (en) * | 1986-04-09 | 1997-10-29 | Eli Lilly And Company | A method of using eukaryotic expression vectors comprising the bk virus enhancer |
DK323587D0 (da) * | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
JPH03501921A (ja) * | 1987-05-18 | 1991-05-09 | インテグレイテッド・ジェネティクス・インク | 改良タンパク質分子、並びにその製造及び活性化方法 |
JP2799316B2 (ja) * | 1987-06-12 | 1998-09-17 | ヘキスト・マリオン・ルセル株式会社 | 雑種ヒトプロテインcおよびその遺伝子工学的製法 |
US5084274A (en) * | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
US4992373A (en) * | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
CA1340740C (en) * | 1987-12-08 | 1999-09-14 | Eileen R. Mulvihill | Co-expression in eukaryotic cells |
ZA889497B (en) * | 1987-12-28 | 1990-08-29 | Lilly Co Eli | Vectors and compounds for expression of zymogen forms of human protein c |
JP2643968B2 (ja) * | 1988-02-03 | 1997-08-25 | サントリー株式会社 | Kex2エンドプロテアーゼ及びその製造方法 |
JP2728240B2 (ja) * | 1988-07-26 | 1998-03-18 | ヘキスト薬品工業株式会社 | ヒトプロテインc変異体及びその製造方法 |
JPH0246296A (ja) * | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインc及びその製造方法 |
FI85342C (fi) * | 1989-02-03 | 1992-04-10 | Tampella Oy Ab | Foerfarande och anordning foer befuktning av partiklar i gasstroemningen. |
CA2047702C (en) * | 1989-03-06 | 2000-10-24 | Joseph F. Sambrook | Serpin resistant chymotrypsin superfamily proteases particularly pai-1 resistant t-pa, complementary inhibitor mutants; compositions; genes; expression |
JP3045307B2 (ja) * | 1989-08-11 | 2000-05-29 | ザイモジェネティクス,インコーポレイティド | 活性化プロテインcを生成するための細胞培養法 |
-
1990
- 1990-12-28 ES ES91901991T patent/ES2113878T3/es not_active Expired - Lifetime
- 1990-12-28 EP EP91901991A patent/EP0506821B1/en not_active Expired - Lifetime
- 1990-12-28 CA CA002071630A patent/CA2071630C/en not_active Expired - Lifetime
- 1990-12-28 AT AT91901991T patent/ATE163048T1/de not_active IP Right Cessation
- 1990-12-28 AU AU71685/91A patent/AU7168591A/en not_active Abandoned
- 1990-12-28 DE DE69032029T patent/DE69032029T2/de not_active Expired - Fee Related
- 1990-12-28 WO PCT/US1990/007693 patent/WO1991009960A1/en active IP Right Grant
- 1990-12-28 JP JP50294991A patent/JP3270462B2/ja not_active Expired - Fee Related
- 1990-12-28 DK DK91901991.9T patent/DK0506821T3/da active
-
1994
- 1994-10-05 US US08/318,579 patent/US5766921A/en not_active Expired - Fee Related
-
1998
- 1998-03-20 GR GR980400604T patent/GR3026414T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0506821A1 (en) | 1992-10-07 |
JP3270462B2 (ja) | 2002-04-02 |
CA2071630C (en) | 2000-02-22 |
DE69032029D1 (de) | 1998-03-12 |
WO1991009960A1 (en) | 1991-07-11 |
US5766921A (en) | 1998-06-16 |
CA2071630A1 (en) | 1991-06-30 |
EP0506821A4 (en) | 1992-11-04 |
EP0506821B1 (en) | 1998-02-04 |
GR3026414T3 (en) | 1998-06-30 |
AU7168591A (en) | 1991-07-24 |
DE69032029T2 (de) | 1998-08-20 |
DK0506821T3 (da) | 1998-03-30 |
ATE163048T1 (de) | 1998-02-15 |
JPH06502986A (ja) | 1994-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2113878T3 (es) | Proteina c hibrida. | |
MX9606386A (es) | Agentes que afectan la hemostasis trombotica. | |
DE3484616D1 (de) | Enzymwiderstandsfaehige immunomodulatorische peptide. | |
FI905956A0 (fi) | Foerfarande foer producering av ett biologiskt aktivt protein. | |
DE68929043D1 (de) | Für androgen-rezeptor-protein kodierende dna | |
GR3025596T3 (en) | Compositions and methods for identifying biologically active molecules. | |
ATE312119T1 (de) | Glucagonähnliche peptide, zusammensetzungen und verfahren | |
DE69430253D1 (de) | Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen | |
DE69133509D1 (de) | Verfahren zur herstellung von beta-lactamen | |
DE60102147D1 (de) | Anti-gefrier proteine, deren herstellung und verwendung | |
ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit | |
DE69510356D1 (de) | Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie | |
ATE343398T1 (de) | Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge | |
HUT58765A (en) | Process for producing peptide compounds and pharmaceutical compositions containing them as active components | |
ATE211390T1 (de) | Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung | |
EA199700241A1 (ru) | Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран | |
AR004093A1 (es) | El uso de una proteina derivada de una quimioquina de mamifero y un medicamento util para movilizar celulas tronco hematopoyeticas. | |
DE69113049D1 (de) | Varianten des gewebeplasminogenaktivators mit vermindertem abbau. | |
ATE85893T1 (de) | Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis. | |
ATE452139T1 (de) | Peptid-köder zur herstellung von medikamenten, die für die prävention oder behandlung von autoimmunerkrankungen bzw. problemen, die mit dem auftreten von gegen exogene proteine gerichteten antikörpern in zusammenhang stehen, bestimmt sind | |
BG60657B2 (en) | Human recombinant interleukin-2 muteins | |
UA23145A (uk) | Спосіб визhачеhhя активhості бромелаїhу | |
DE60326157D1 (de) | Verfahren zur identifizierung von modulatoren der glucoseaufnahme | |
ES2004438A6 (es) | Un metodo para producir una proteina trombolitica | |
MX9504057A (es) | Proteina que tiene actividad tpo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 506821 Country of ref document: ES |